Genetron Holdings Limited

Genetron Holdings Limited

Genetron Holdings Limited was founded as a precision oncology platform, offering a range of genomic profiling and liquid biopsy services for cancer management. The company's operations span from early cancer screening to treatment monitoring, with a geographic footprint that includes major offices in Beijing, Suzhou, and Shanghai, alongside research facilities in the United States. The firm's strategy integrates next-generation sequencing (NGS) with AI/ML algorithms to analyze circulating tumor DNA. Its product portfolio includes the Genetron One test, a comprehensive genomic profiling assay, and HCCscreen, a liquid biopsy test for early detection of hepatocellular carcinoma. Genetron has established partnerships with pharmaceutical companies for clinical trial enrollment and drug development, serving as a central lab for biopharma clients. The company also operates a molecular pathology laboratory in Suzhou. Genetron's corporate structure has evolved since its 2020 IPO on the Nasdaq, with the company now focused on commercializing its HCCscreen test for chronic hepatitis B carriers. In 2022, the firm reported collaborations with over 50 hospitals and healthcare institutions across China for clinical validation studies of its liquid biopsy platform. No recent operational events from the last 24 months were verifiable from public records available to this model. A structural differentiator is Genetron's dual revenue model: it generates income both from direct clinical testing services and from diagnostic service fees paid by pharmaceutical partners for drug development support. This hybrid approach, combining diagnostics with a contract research organization (CRO) function, is relatively rare among Chinese precision oncology firms.